78.93
price up icon6.06%   4.51
after-market アフターアワーズ: 78.93
loading
前日終値:
$74.42
開ける:
$76
24時間の取引高:
934.87K
Relative Volume:
1.22
時価総額:
$6.44B
収益:
$39.21M
当期純損益:
$-311.35M
株価収益率:
-21.45
EPS:
-3.6793
ネットキャッシュフロー:
$-234.34M
1週間 パフォーマンス:
-0.27%
1か月 パフォーマンス:
-12.96%
6か月 パフォーマンス:
+46.89%
1年 パフォーマンス:
+148.05%
1日の値動き範囲:
Value
$75.71
$81.31
1週間の範囲:
Value
$73.31
$81.53
52週間の値動き範囲:
Value
$19.45
$103.00

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
名前
Kymera Therapeutics Inc
Name
セクター
Healthcare (1114)
Name
電話
857-285-5314
Name
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
職員
238
Name
Twitter
Name
次回の収益日
2025-08-01
Name
最新のSEC提出書
Name
KYMR's Discussions on Twitter

Compare KYMR vs VRTX, REGN, ALNY, ARGX, INSM

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
KYMR icon
KYMR
Kymera Therapeutics Inc
78.93 6.08B 39.21M -311.35M -234.34M -3.6793
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
454.97 113.96B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
749.47 78.41B 14.34B 4.50B 3.77B 41.56
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
328.70 40.85B 3.71B 313.75M 465.38M 2.2571
ARGX icon
ARGX
Argen X Se Adr
697.05 42.05B 4.16B 1.29B 734.26M 19.58
INSM icon
INSM
Insmed Inc
148.31 29.99B 606.42M -1.28B -997.58M -6.403

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-16 再開されました Jefferies Buy
2026-01-28 再開されました Barclays Overweight
2026-01-06 ダウングレード Wolfe Research Outperform → Peer Perform
2025-11-03 再開されました Guggenheim Buy
2025-10-24 繰り返されました B. Riley Securities Buy
2025-10-21 開始されました Mizuho Outperform
2025-09-18 繰り返されました H.C. Wainwright Buy
2025-09-17 開始されました Barclays Overweight
2025-09-16 開始されました RBC Capital Mkts Outperform
2025-07-30 再開されました B. Riley Securities Buy
2025-07-03 再開されました Morgan Stanley Overweight
2025-06-03 アップグレード B. Riley Securities Neutral → Buy
2025-06-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-06-02 アップグレード BofA Securities Neutral → Buy
2025-05-20 再開されました Stifel Buy
2025-03-13 開始されました Citigroup Buy
2024-12-10 開始されました BTIG Research Buy
2024-12-06 開始されました BMO Capital Markets Market Perform
2024-12-02 アップグレード Wells Fargo Equal Weight → Overweight
2024-11-18 開始されました Stephens Overweight
2024-09-09 再開されました Leerink Partners Outperform
2024-08-26 アップグレード Wolfe Research Peer Perform → Outperform
2024-04-22 開始されました Oppenheimer Outperform
2024-02-15 開始されました Wolfe Research Peer Perform
2024-01-04 アップグレード JP Morgan Neutral → Overweight
2024-01-03 ダウングレード BofA Securities Buy → Neutral
2023-12-19 ダウングレード Wells Fargo Overweight → Equal Weight
2023-06-30 開始されました Truist Buy
2023-05-05 アップグレード Raymond James Mkt Perform → Outperform
2022-12-06 ダウングレード Credit Suisse Outperform → Neutral
2022-11-08 開始されました Raymond James Mkt Perform
2022-08-15 開始されました Jefferies Buy
2022-08-03 開始されました Goldman Buy
2022-07-20 開始されました SVB Leerink Mkt Perform
2022-04-28 開始されました Credit Suisse Outperform
2022-03-10 開始されました JP Morgan Neutral
2022-02-10 開始されました Wells Fargo Overweight
2021-09-30 開始されました B. Riley Securities Neutral
2021-09-30 開始されました Stifel Buy
2021-09-10 ダウングレード BofA Securities Buy → Neutral
2021-05-21 開始されました UBS Buy
2021-04-14 開始されました Berenberg Buy
2020-12-04 開始されました H.C. Wainwright Buy
2020-09-15 開始されました BofA Securities Neutral
2020-09-15 開始されました Cowen Outperform
2020-09-15 開始されました Guggenheim Buy
2020-09-15 開始されました Morgan Stanley Equal-Weight
すべてを表示

Kymera Therapeutics Inc (KYMR) 最新ニュース

pulisher
Mar 25, 2026

Kymera Therapeutics (NASDAQ:KYMR) COO Sells $7,063,662.50 in Stock - MarketBeat

Mar 25, 2026
pulisher
Mar 25, 2026

Jeremy Chadwick Sells 24,727 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat

Mar 25, 2026
pulisher
Mar 25, 2026

Kymera Therapeutics (NASDAQ:KYMR) Shares Up 8.4%What's Next? - MarketBeat

Mar 25, 2026
pulisher
Mar 24, 2026

Kymera Therapeutics (KYMR) to present Phase 1b BroADen trial data for KT-621 at AAD 2026 - MSN

Mar 24, 2026
pulisher
Mar 24, 2026

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Mar 24, 2026
pulisher
Mar 23, 2026

A Look At Kymera Therapeutics (KYMR) Valuation After Late Breaking KT-621 AAD 2026 Selection - Sahm

Mar 23, 2026
pulisher
Mar 22, 2026

Kymera’s KT-621 Faces "Sell the News" Risk as AAD Data and Dilution Collide - Bitget

Mar 22, 2026
pulisher
Mar 21, 2026

Jobs Data: Can Kymera Therapeutics Inc benefit from deglobalization2026 Retail & Safe Entry Point Identification - baoquankhu1.vn

Mar 21, 2026
pulisher
Mar 21, 2026

Kymera Q4 loss wider than expected, cash boost extends runway - MSN

Mar 21, 2026
pulisher
Mar 20, 2026

Esposito sells Kymera (KYMR) shares worth $197,877 By Investing.com - Investing.com Canada

Mar 20, 2026
pulisher
Mar 20, 2026

Kymera Therapeutics (KYMR) director exercises options, sells 2,500 shares under 10b5-1 plan - Stock Titan

Mar 20, 2026
pulisher
Mar 20, 2026

Kymera Therapeutics (KYMR) to Present Phase 1b BroADen Trial Data for KT-621 at AAD 2026 - Insider Monkey

Mar 20, 2026
pulisher
Mar 20, 2026

Stock Recap: Is Kymera Therapeutics Inc currently under institutional pressure2026 Closing Moves & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn

Mar 20, 2026
pulisher
Mar 20, 2026

Highs Report: Is now the right time to enter Kymera Therapeutics IncMarket Performance Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn

Mar 20, 2026
pulisher
Mar 19, 2026

(KYMR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Mar 19, 2026
pulisher
Mar 19, 2026

Nextech Invest Sells $4.19M in Kymera Shares, Stake Value Rises to $21.7MNews and Statistics - IndexBox

Mar 19, 2026
pulisher
Mar 19, 2026

Nextech Trims Kymera at a Recent High — think Foolishly before acting. - Yahoo Finance

Mar 19, 2026
pulisher
Mar 19, 2026

15 Most Promising Stocks Under $100 to Buy - Insider Monkey

Mar 19, 2026
pulisher
Mar 18, 2026

Aug Selloffs: What is the long term forecast for Kymera Therapeutics Inc stock2026 Market Sentiment & Pattern Based Trade Signal System - baoquankhu1.vn

Mar 18, 2026
pulisher
Mar 18, 2026

Aug Breakouts: What is Kymera Therapeutics Incs 5 year growth outlookPortfolio Return Report & Consistent Return Strategy Ideas - baoquankhu1.vn

Mar 18, 2026
pulisher
Mar 17, 2026

Weekly Earnings: Is Kymera Therapeutics Inc currently under institutional pressure2026 Price Momentum & Smart Investment Allocation Insights - baoquankhu1.vn

Mar 17, 2026
pulisher
Mar 17, 2026

HighVista Strategies LLC Makes New $890,000 Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Mar 17, 2026
pulisher
Mar 17, 2026

Holocene Advisors LP Acquires New Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Mar 17, 2026
pulisher
Mar 16, 2026

KYMR: Jefferies Lowers Price Target but Maintains Buy Rating | KYMR Stock News - GuruFocus

Mar 16, 2026
pulisher
Mar 16, 2026

Jefferies Financial Group Initiates Coverage on Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat

Mar 16, 2026
pulisher
Mar 15, 2026

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2025 earnings call transcript - MSN

Mar 15, 2026
pulisher
Mar 15, 2026

Boxer Capital Management LLC Lowers Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Mar 15, 2026
pulisher
Mar 15, 2026

Kymera Therapeutics, Inc. $KYMR Shares Sold by Checkpoint Capital L.P. - MarketBeat

Mar 15, 2026
pulisher
Mar 15, 2026

Braidwell LP Takes $15.66 Million Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Mar 15, 2026
pulisher
Mar 14, 2026

Kymera Trials IRF5 And STAT6 Degraders As Market Weighs Long Term Upside - Yahoo Finance

Mar 14, 2026
pulisher
Mar 14, 2026

Kymera Therapeutics, Inc. $KYMR Stock Position Lessened by Avoro Capital Advisors LLC - MarketBeat

Mar 14, 2026
pulisher
Mar 14, 2026

Can Kymera Therapeutics’ (KYMR) Oral Degraders Redefine Its Long-Term Edge Over Biologic Rivals? - simplywall.st

Mar 14, 2026
pulisher
Mar 12, 2026

Kymera at Barclays Conference: Strategic Focus on Immunology By Investing.com - Investing.com Canada

Mar 12, 2026
pulisher
Mar 12, 2026

KYMR: Advancing oral immunology therapies with robust pipeline and strong financial runway - TradingView

Mar 12, 2026
pulisher
Mar 12, 2026

Kymera Therapeutics CFO presents new immunology strategy at Barclays Healthcare Conference - Traders Union

Mar 12, 2026
pulisher
Mar 12, 2026

Morgan Stanley maintains Kymera Therapeutics (KYMR) overweight recommendation - MSN

Mar 12, 2026
pulisher
Mar 12, 2026

Kymera Therapeutics, Inc. $KYMR Holdings Trimmed by Atika Capital Management LLC - MarketBeat

Mar 12, 2026
pulisher
Mar 11, 2026

Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 25,758 Shares - MarketBeat

Mar 11, 2026
pulisher
Mar 11, 2026

Kymera Therapeutics COO Sells Shares Worth Over $2 Million - TradingView

Mar 11, 2026
pulisher
Mar 11, 2026

Kymera (NASDAQ: KYMR) COO exercises 20,000 options and sells 25,758 shares - Stock Titan

Mar 11, 2026
pulisher
Mar 11, 2026

Jeremy Chadwick reports KYMR transactions (NASDAQ: KYMR) including 20,000-option line - Stock Titan

Mar 11, 2026
pulisher
Mar 11, 2026

Hedge Fund Moves: Can Kymera Therapeutics Inc weather a recessionVolume Spike & Daily Chart Pattern Signals - baoquankhu1.vn

Mar 11, 2026
pulisher
Mar 11, 2026

Kymera to present atopic dermatitis trial data at AAD meeting By Investing.com - Investing.com Canada

Mar 11, 2026
pulisher
Mar 10, 2026

Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Clinical Trial of KT-621 - MSN

Mar 10, 2026
pulisher
Mar 10, 2026

Kymera at Leerink Global Healthcare: Strategic Insights on Drug Development By Investing.com - Investing.com Canada

Mar 10, 2026
pulisher
Mar 10, 2026

KYMR: KT-621 shows strong early efficacy and safety; pivotal Phase 2b readouts expected in 2027 - TradingView

Mar 10, 2026
pulisher
Mar 10, 2026

Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology Annual Meeting - Investing News Network

Mar 10, 2026
pulisher
Mar 10, 2026

Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting - Bitget

Mar 10, 2026
pulisher
Mar 10, 2026

Experimental atopic dermatitis pill KT-621 heads to late-breaking AAD stage - Stock Titan

Mar 10, 2026
pulisher
Mar 09, 2026

Kymera CEO Nello Mainolfi’s Boldest Line Had Nothing to Do With the Earnings Miss - Yahoo Finance

Mar 09, 2026
pulisher
Mar 09, 2026

Market Moves: What is the long term forecast for Kymera Therapeutics Inc. stockWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn

Mar 09, 2026

Kymera Therapeutics Inc (KYMR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$27.36
price up icon 1.82%
$47.03
price up icon 3.20%
$53.54
price up icon 4.29%
$88.77
price up icon 2.26%
ONC ONC
$283.45
price up icon 2.81%
$148.31
price up icon 6.59%
大文字化:     |  ボリューム (24 時間):